Surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 heart valve are associated with a similar risk of major adverse cardiovascular and renal events and similar durability in patients with chronic kidney disease (CKD) at 5 years, according to an analysis of pooled registry data.